Patents by Inventor Patrick L. Ahl
Patrick L. Ahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20260325629Abstract: Backgrounds: The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand pneumococcal disease protection. This phase 3 study evaluated key safety and immunogenicity data of PCV20 with a 4-dose infant immunization series. Methods: In this phase 3, double-blind study (NCT04382326) conducted in the United States and Puerto Rico, healthy infants were randomized equally to receive 4 doses of PCV20 or PCV13 at 2, 4, 6, and 12-15 months of age. Objectives included noninferiority of immunoglobulin G (IgG) geometric mean concentrations (GMCs; 2-fold criterion) at 1 month after Dose 4 (co-primary) and Dose 3 (key secondary), and participants (%) with predefined IgG concentrations 1 month after Dose 3 (co-primary; 10% criterion). The 7 additional PCV20 serotypes were compared with the lowest result among vaccine serotypes in the PCV13 group for noninferiority evaluation. Other objectives included demonstration of opsonophagocytic activity (OPA) and boosting responses.Type: ApplicationFiled: May 16, 2024Publication date: October 22, 2026Applicant: MERCK SHARP & DOHME LLCInventors: Patrick L. AHL, Peter J. MANLEY, Izzat T. RAHEEM, W. Michael SEGANISH, William J. SMITH
-
Publication number: 20240408188Abstract: The present disclosure provides, among other things, a vaccine composition that includes a squalene nanoemulsion (SNE) adjuvant and HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.Type: ApplicationFiled: June 6, 2024Publication date: December 12, 2024Applicant: Merck Sharp & Dohme LLCInventors: Patrick L. Ahl, William J. Smith, Randal J. Soukup, Nicole Lea Sullivan, John Gaspar, Julie M. Skinner
-
Publication number: 20240390471Abstract: The invention relates to novel compounds and formulations. Further, the invention relates to novel compounds and formulations useful in pneumococcal and pneumococcal conjugate vaccines. More specifically, the invention relates to compositions comprising pneumococcal conjugates and one or more compounds of Formula I, Ia, II, IIa, III, IIIa, IV, or IVa, or a pharmaceutically acceptable salt thereof, prepared as stable nanoemulsions (herein referred to as “SNE adjuvant compositions” or “SNEs”).Type: ApplicationFiled: May 16, 2024Publication date: November 28, 2024Applicant: Merck Sharp & Dohme LLCInventors: Patrick L. Ahl, Peter J. Manley, Izzat T. Raheem, W. Michael Seganish, William J. Smith
-
Publication number: 20240108710Abstract: The present invention relates generally to the prevention of pneumococcal disease. More specifically, the invention relates to a composition comprising pneumococcal conjugates and a stable nanoemulsion (SNE).Type: ApplicationFiled: February 2, 2022Publication date: April 4, 2024Applicant: Merck Sharp & Dohme LLCInventors: William J. Smith, Patrick L. Ahl, Randal J. Soukup, Julie M. Skinner
-
Patent number: 9573811Abstract: The present invention relates to methods for preparing amorphous aluminum hydroxyphosphate. An aluminum salt and a phosphate solution are co-mixed at a constant ratio in the presence of a buffer. Preferably, an excess of the phosphate solution is used to act as a buffer. Due to the presence of a buffer, the pH is maintained constant during reaction (after initial rapid equilibration) without active adjustment. The methods are particularly applicable for the large scale manufacturing of aluminum phosphate adjuvant. Aluminum phosphate is used as an adjuvant in vaccine formulations, particularly those including a protein or saccharide antigen.Type: GrantFiled: November 19, 2012Date of Patent: February 21, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: David S. Thiriot, Patrick L. Ahl, Jayme Cannon, Gabriel M. Lobel
-
Publication number: 20140314653Abstract: The present invention relates to methods for preparing amorphous aluminum hydroxyphosphate. An aluminum salt and a phosphate solution are co-mixed at a constant ratio in the presence of a buffer. Preferably, an excess of the phosphate solution is used to act as a buffer. Due to the presence of a buffer, the pH is maintained constant during reaction (after initial rapid equilibration) without active adjustment. The methods are particularly applicable for the large scale manufacturing of aluminum phosphate adjuvant. Aluminum phosphate is used as an adjuvant in vaccine formulations, particularly those including a protein or saccharide antigen.Type: ApplicationFiled: November 19, 2012Publication date: October 23, 2014Inventors: David S. Thiriot, Patrick L. Ahl, Jyme Cannon, Gabriel M. Lobel
-
Patent number: 8192746Abstract: The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM197. The immunogenic composition, preferably formulated as a vaccine on an aluminum -based adjuvant, provides broad coverage against pneumococcal disease, particularly in infants and young children.Type: GrantFiled: February 3, 2011Date of Patent: June 5, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Michael J. Caulfield, Patrick L. Ahl, Jeffrey T. Blue, Jayme L. Cannon
-
Publication number: 20110195086Abstract: The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F or 33F) conjugated to a carrier protein, preferably CRM197. The immunogenic composition, preferably formulated as a vaccine on an aluminum-based adjuvant, provides broad coverage against pneumococcal disease, particularly in infants and young children.Type: ApplicationFiled: February 3, 2011Publication date: August 11, 2011Inventors: Michael J. CAULFIELD, Patrick L. Ahl, Jeffrey T. Blue, Jayme L. Cannon
-
Patent number: 6339069Abstract: Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat mammals for diseases, disorders or conditions, e.g., tumors, microbial infection and inflammations, characterized by the occurrence of peptidase-secreting cells.Type: GrantFiled: June 29, 1999Date of Patent: January 15, 2002Assignee: Elan PharmaceuticalsTechnologies, Inc.Inventors: Paul R. Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J. Craig Franklin, Ravi K. Erukulla, Donna Cabral-Lilly, Patrick L. Ahl
-
Patent number: 6086851Abstract: This invention provides a composition containing a sized liposome comprising a lipid and an inducer; the sized liposome has a diameter of at most about 1 micron and the inducer is present in an amount effective to induce interdigitation-fusion of the sized liposome. Also provided herein are interdigitation-fusion liposomes and gels, and methods of making the same.Type: GrantFiled: June 24, 1997Date of Patent: July 11, 2000Assignee: The Liposome Company, Inc.Inventors: Lawrence T. Boni, Andrew S. Janoff, Sharma R. Minchey, Walter R. Perkins, Christine E. Swenson, Patrick L. Ahl, Thomas S. Davis
-
Patent number: 5820848Abstract: This invention provides a composition containing a sized liposome comprising a lipid and an induce; the sized liposome has a diameter of at most about 1 micoron and the induces is present in an amount effective to induce interdigitation-fusion of the sized liposome. Also provided herein are interdigitation-fusion liposomes and gels, and methods of making the same.Type: GrantFiled: September 30, 1994Date of Patent: October 13, 1998Assignee: The Liposome Company, Inc.Inventors: Lawrence T. Boni, Andrew S. Janoff, Sharma R. Minchey, Walter R. Perkins, Christine E. Swenson, Patrick L. Ahl, Thomas S. Davis
-
Patent number: 5662930Abstract: Provided herein is a method of administering a liposome composition to an animal, the method involving adminstering to the animal a liposome composition containing an adverse physiological reaction-reducing effective amount of a liposome which has, in addition to a bioactive agent, a lipid bilayer containing a lipid and a surface agent-modified molecule. An adverse physiological reaction which may be experienced by the animal upon administration of a liposome composition is reduced by way of the presence of the surface agent-modified molecule in the liposome's lipid bilayer.Type: GrantFiled: May 4, 1995Date of Patent: September 2, 1997Assignee: The Liposome Company, Inc.Inventors: Patrick L. Ahl, Suresh K. Bhatia, Sharma R. Minchey, Andrew S. Janoff
-
Patent number: 5614214Abstract: Provided herein is a method of administering a liposome composition to an animal, the method involving adminstering to the animal a liposome composition containing an adverse physiological reaction-reducing effective amount of a liposome which has, in addition to a bioactive agent, a lipid bilayer containing a lipid and a surface agent-modified molecule. An adverse physiological reaction which may be experienced by the animal upon administration of a liposome composition is reduced by way of the presence of the surface agent-modified molecule in the liposome's lipid bilayer.Type: GrantFiled: May 20, 1994Date of Patent: March 25, 1997Assignee: The Liposome Company, Inc.Inventors: Patrick L. Ahl, Suresh K. Bhatia, Sharma R. Minchey, Andrew S. Janoff